The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses direct against EBV lymphoblastoid cell lines

Vaccine

Volumn 17, Issue 9-10, 1999, Pages 1282-1290

  Wilson, A D ^a   Lovgren Bengtsson K ^c   Villacres Ericsson, M ^b   Morein, B ^b   Morgan, A J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b Section of Virology   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cytotoxic T cell; Epstein Barr virus; Iscom; Vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; EPSTEIN BARR VIRUS VACCINE; GLYCOPROTEIN GP 340; ISCOM; NEUTRALIZING ANTIBODY; PERIODATE SODIUM; PHOSPHATIDYLETHANOLAMINE; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; EPSTEIN BARR VIRUS; IMMUNIZATION; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD4-CD8 RATIO; CELL DIVISION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HERPESVIRUS 4, HUMAN; ISCOMS; MICE; OLEANOLIC ACID; PROTEIN DENATURATION; RECOMBINANT PROTEINS; SAGUINUS; SAPOGENINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VIRAL MATRIX PROTEINS;

EID: 0344197071     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00351-X     Document Type: Article

References (34)

1. Henle G., Henle W., Diehl V. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA. 59:1968;94-101.
2. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res. 55:1990;133-270.
3. Niedobitek G., Agathanggelou A., Nicholls J.M. Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol. 7:1996;165-174.
4. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM et al., editors. Fields virology, vol. 2. New York: Lippincot-Raven, 1996. p. 2397-446.
5. Callan M.F.C., Steven N., Krausa P., Wilson J.D.K., Moss P.A.H., Gillespie G.M., Bell J.I., Rickinson A.B., McMichael A.J. Large clonal expansions of CD8+ T-cells in acute infectious mononucleosis. Nature Med. 2:1996;906-911.
6. Andersson J. Clinical and immunological considerations in Epstein-Barr virus-associated diseases. Scand J Infect Dis. 100 (Suppl.):1996;72-82.
7. Evans AS. Epstein-Barr vaccine: use in IM. In: Tursz T, Pagano JS, Ablashi DV, de The G, Lenoir G, Pearson GR, editors. The Epstein-Barr virus and associated diseases. London: J. Libbey and Paris: INSERM, 1993. p. 593-8.
8. Miyashita E.M., Yang B., Babcock G.J., Thorley-Lawson D.A. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B-cell. J Virol. 71:1997;4882-4891.
9. Khanna R., Burrows S.R., Moss D.J. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev. 59:1995;387-405.
10. Hanto D.W. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med. 46:1995;381-394.
11. Morgan A.J. The development of Epstein-Barr virus vaccines. Vaccine. 10:1992;563-571.
12. Moss D.J., Schmidt C., Elliot S., Suhrbier A., Burrows S., Khanna R. Strategies involved in developing an effective vaccine for EBV-associated diseases. Adv Cancer Res. 69:1996;213-246.
13. Epstein M.A., Randle B.J., Finerty S., Kirkwood J. Not all potentially neutralising vaccine induced antibodies to Epstein Barr virus ensure protection of susceptible animals. Clin Exp Immunol. 63:1986;485-490.
14. Morgan A.J., Mackett M., Finerty S., Arrand J.R., Scullion F.T., Epstein M.A. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins againbst virus-induced malignant lymphomas. J Med Virol. 25:1988;189-195.
15. Finerty S., Scullion F.T., Morgan A.J. Demonstration in vitro of cell-mediated immunity to Epstein-Barr virus in cottontop tamarins. Clin Exp Immunol. 73:1988;181-185.
16. Wilson D., Shooshstari M., Morgan A.J. Virus-specific cytotoxic T-cell responses are associated with immunity of the cottontop tamarin to Epstein-Barr virus. Clin Exp Immunol. 103:1996;199-205.
17. Morein B., Lovgren K., Ronnberg B., Sjolander A., Villacres-Eriksson M. Immunostimulating complexes. Clinical potential in vaccine development. Clin Immunother. 3:1995;461-475.
18. Morgan A.J., Finerty S., Lovgren K., Scullion F.T., Morein B. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. J Gen Virol. 69:1988;2093-2096.
19. + T-cell clones specific for the major envelope glycoprotein gp340. Eur J Immunol. 18:1988;1689-1697.
20. + T-cell epitopes of the candidate Epstein-Barr virus vaccine glycoprotein gp340. J Virol. 65:1991;3821-3828.
21. Bejerano M.T., Masucci M.G., Morgan A., Morein B., Klein G., Klein E. Epstein-Barr virus (EBV) antigens processed and presented by B-cells, B blasts and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation. J Virol. 64:1990;1398-1401.
22. Villacres-Eriksson M., Behboudi S., Morgan A.J., Trinchieri G., Morein B. Immunomodulation of Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response. Cytokine. 9:1997;73-82.
23. Dotsika E., Karagouni E., Sundquist B., Morein B., Morgan A.J., Villacres-Eriksson M. Influence of the Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein-Barr virus (EBV) iscoms. Scand J Immunol. 45:1997;261-268.
24. Madej M., Conway M.J., Morgan A.J., Sweet J., Wallace L., Arrand J., Mackett M. Purification and characterisation of Epstein-Barr virus gp340/220 produced by a bovine papilloma virus vector system. Vaccine. 10:1992;777-782.
25. Wilson AD, Morgan AJ. Indirect measurement of Epstein-Barr virus neutralising antibodies by ELISA. J Virol Methods, 1998;73:11 - 19.
26. Hoffman G.J., Lazarowitz S.G., Hayward S.D. Monoclonal antibody against a 250,000-Da glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci USA. 77:1980;2979-2983.
27. Wilson A.D., Shooshthari M., Finerty S., Watkins P., Morgan A.J. Selection of monoclonal antibodies for the identification of lymphocyte surface antigens in the New World primate Sauinus oedipus oedipus (cottontop tamarin). J Immunol Methods. 178:1995;195-200.
28. Qualtiere L.F., Decoteau J.F., Hassan Nasr-el-Din M. Epitope mapping of the major Epstein-Barr virus outer envelope glycoprotein gp350/220. J Gen Virol. 68:1987;535-543.
29. Ragot T., Finerty S., Watkins P.E., Perricaudet M., Morgan A.J. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the tamarin. J Gen Virol. 74:1993;501-507.
30. Morgan A.J., Smith A.R., Barker R.N., Epstein M.A. A structural investigation of the Epstein-Barr (EB) virus membrane antigen glycoprotein gp340. J Gen Virol. 65:1984;397-404.
31. Watkins D., Letvin N.L., Hughes A.L., Tedder T.F. Molecular cloning of cDNA that encode MHC class I molecules from a new world primate (Saguinus oedipus). J Immunol. 144:1990;1136-1143.
32. Braud V.M., Allan D.S.J., Wilson D., McMichael A.J. TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol. 8:1997;1-10.
33. Braud V.M., Allan D.S.J., O'Callaghan C.A., Söderström K., D'Andrea A., Ogg G.S., Lazetic S., Young N.T., Bell J.I., Philips J.H., Lanier L., McMichael A.J. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 391:1998;705-799.
34. Wilson A.D., Redchenko I., Williams N.A., Morgan A.J. CD4+ T-cells inhibit growth of Epstein-Barr virus-transformed B-cells through CD95/CD95 ligand mediated apoptosis. Int Immunol. 10:1998;1149-1157.